Biovitrum's and Syntonix's Novel Factor IXFc for Hemophilia B has Received Orphan Drug Designation From the FDA

27-Nov-2008 - Biovitrum AB and Syntonix Pharmaceuticals, Inc., a subsidiary of Biogen Idec announced that the company's FIXFc compound for the control and prevention of hemorrhagic episodes in patients with hemophilia B has received an orphan-drug designation from the US Food and Drug Administration (FDA). ...

Biovitrum and Syntonix begin phase I/IIa clinical trial of long-acting recombinant Factor IXFc for treatment of Hemophilia B

06-Mar-2008 - Biovitrum AB and Syntonix Pharmaceuticals, Inc. have obtained approval from the US Food and Drug Administration to commence a clinical phase I/IIa study of a long-acting, recombinant Factor IXFc for the treatment of Hemophilia B. The US Food and Drug Administration (FDA) has approved the ...

Biogen Idec to acquire Syntonix

08-Jan-2007 - Biogen Idec and Syntonix Pharmaceuticals announced that the companies have signed a definitive agreement for the acquisition of Syntonix by Biogen Idec. Syntonix, a privately held biopharmaceutical company focused on discovering and developing long-acting therapeutic products to improve treatment ...

Serono and Syntonix to pursue the development of long-acting, inhaleable therapy to treat infertility

Second Agreement Between Companies Builds on Interferon-beta SynFusion Program

19-Sep-2006 - Serono and Syntonix Pharmaceuticals Inc. announced that they have entered into an agreement under which the companies will evaluate Syntonix' FSH:Fc SynFusionTM products for further development. Syntonix' SynFusion and TransceptorTM technologies may enable the development of a long-acting FSH ...

Biovitrum and Syntonix enter agreement for the joint development and commercialization for the treatment of Hemophilia

25-Jan-2006 - Biovitrum AB and Syntonix Pharmaceuticals, Inc. have entered into a co-development and commercialization agreement for Syntonix' long-acting, recombinant Factor IX product for Hemophilia B ("FIX:Fc"). Under the terms of the agreement, Syntonix receives an initial collaboration fee and Biovitrum ...